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ORIGINAL ARTICLE
miR-151a induces partial EMT by regulating E-cadherin
in NSCLC cells
I Daugaard1,2, KJ Sanders1, A Idica1, K Vittayarukskul1, M Hamdorf1, JD Krog1,2, R Chow1, D Jury1, LL Hansen2, H Hager3,4, P Lamy5,
CL Choi1, D Agalliu6, DG Zisoulis1 and IM Pedersen1
miR-151a and its host gene, focal adhesion kinase, FAK, are located in a region of chromosome 8q that is frequently ampliﬁed
in solid tumors, including lung cancer. Lung cancer is the leading cause of cancer deaths worldwide and metastasis remains the
major challenge in battling lung cancer mortality. Here, we demonstrate that miR-151a is overexpressed in non-small cell lung
cancer (NSCLC) patient specimens, as compared to healthy lung. In addition, miR-151a overexpression promotes proliferation,
epithelial-to-mesenchymal transition (EMT) and induces tumor cell migration and invasion of NSCLC cells. Blocking miR-151a
expression using anti-miR-151a approaches signiﬁcantly reduced NCSLC cell proliferative and motility potential. Furthermore, we
determined that miR-151a signiﬁcantly regulates E-cadherin expression. Finally, functional rescue experiments determined that
overexpression of E-cadherin in miR-151a NSCLC cell lines potently repressed miR-151a-induced partial EMT and cell migration of
NSCLC cells. In conclusion, our ﬁndings suggest that miR-151a functions as an oncomiR in NSCLC by targeting E-cadherin mRNA
and inducing proliferation, migration and partial EMT.
Oncogenesis (2017) 6, e366; doi:10.1038/oncsis.2017.66; published online 31 July 2017
INTRODUCTION
Lung cancer has the highest mortality rate amongst human
malignancies and is each year liable for 1.5 million deaths
worldwide.1 Approximately 85% of all lung cancers are non-small
cell lung cancer (NSCLC), which develop as a consequence of both
genetic and epigenetic alterations in the epithelial cells of the
lung.2,3 The overall 5-year survival rate for lung cancer is 15%
and only 5% for patients with distant metastatic lesions.2,4,5
Epithelial-to-mesenchymal transition (EMT) is recognized as an
initiating and essential event in the metastatic cascade in
which epithelial cancer cells lose polarity, cell-cell contacts, and
acquire mesenchymal features that enhance their migratory
and invasive properties.6–9 EMT is a complex process involving
a broad spectrum of changes at the molecular level, but
downregulation of E-cadherin is considered a hallmark of
EMT.10,11
MicroRNA (miRs) are a class of small non-coding RNAs (~22 nt),
which regulate gene expression mainly by enhancing messenger
RNA degradation (mRNAs).12 The majority of all protein-encoding
genes are subject to miR regulation and miR dysregulation has
been found to be a common feature in human malignancies,
including lung cancer.13–23 miR-151a and its host gene, focal
adhesion kinase, FAK, are located in a region of chromosome 8q
that is frequently ampliﬁed in solid tumors, including lung
cancer.13–15,24 miR-151a is often expressed with FAK and functions
synergistically, for example, by promoting metastasis in liver and
prostate cancer by inhibiting RhoGDIA.24 Here we show for the
ﬁrst time that miR-151a is overexpressed in primary NSCLC
specimens and induces a mesenchymal-like phenotype, as well as
enhances the proliferative, migratory and invasive properties of
NSCLC cells, by regulating E-cadherin mRNA and protein
expression. Thus, we present a novel mechanism of E-cadherin
regulation during tumor cell proliferation, migration and partial
EMT in NSCLC.
RESULTS
miR-151a is overexpressed in NSCLC
miR-151a has been shown to function synergistically with its host
gene, FAK, which is overexpressed as a result of gene ampliﬁcation
in many types of tumors, including lung cancer, and associated
with poor prognosis.16,17 These ﬁndings warrant studies of a
potential role for miR-151a in NSCLC pathology. We examined
miR-151a expression levels in a cohort of 52 patients diagnosed
with primary lung adenocarcinoma (LAC), which is the
most common subtype of NSCLC.5,18,19 The cohort comprised
52 primary NSCLCs and 26 matched distant metastases
(22 brain and 4 adrenal gland), as well as tumor-adjacent normal
lung samples from 10 patients (Supplementary Table S1). We
validated that miR-151a is expressed in normal lung, brain and
adrenal gland tissue (Supplementary Figure S1) and then
performed miR-speciﬁc RT-qPCR analysis of all primary NSCLCs,
paired distant metastases and tumor-adjacent normal lung
samples. miR-151a expression levels were signiﬁcantly enhanced
in primary tumor as compared to normal lung tissue indicating a
potential role for miR-151a during NSCLC initiation (Figure 1a,
P= 0.0037). Similarly high expression levels were detected in the
paired metastases and the increased expression of miR-151a is
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thus maintained during the metastatic process. Of note, RT-qPCR
analysis was performed on RNA extracted from whole-tissue
sections, where the average tumor cell content was 33.2%
(range= 5–80%, Supplementary Table S1), suggesting that
the observed increase in miR-151a expression may be an
underestimate. This was validated when we next performed
miR-151a in-situ hybridization on tissue from paired primary tumor
and metastatic sites (brain), as well as tumor-adjacent normal
lung, using a scrambled miR control probe as a negative control.
Normal lung tissue showed low miR-151a expression levels
(Figure 1b). In contrast, miR-151a expression levels were
signiﬁcantly induced in primary tumor, as well as in tissue from
the metastatic site (brain) (Figure 1b and Supplementary
Figure S2). Finally, we analyzed publicly available microRNA
expression datasets through The Cancer Genome Atlas
(TGCA) database (https://gdc-portal.nci.nih.gov/). We collected all
the hsa-miR-151a expression values from the 45 LAC patients
with paired tumor-adjacent normal lung and primary tumor
samples available, validating that miR-151a is signiﬁcantly
overexpressed in NSCLC tissue as compared to normal tissue
(Figure 1c, Po0.0001). These results support the idea that
miR-151a functions as a novel oncomiR in NSCLC. We next
initiated analysis to mechanistically characterize miR-151a in
NSCLC pathogenesis.
miR-151a enhances NSCLC cell growth
To investigate if enhanced expression of miR-151a promotes
NSCLC cell tumor cell growth and motility, we generated
miR-modulated NSCLC cell lines using A549 cells (miR-151a
over-expression, anti-miR-151a cell lines in which endogenously
expressed miR-151a is neutralized, and control miR cell lines). miR
modulated NSCLC cell lines were veriﬁed for miR-151a expression
levels and effect on a published miR-151a target, RhoGDIA,24
(Supplementary Figure S3). miR-151a was determined to be 2–4
fold increased in A549 cells over-expressing miR-151a (miR-151a
A549 cells), and 30-50% reduced in anti-miR-151a A549 cells,
relative to miR controls. First, we determined that miR-151a
overexpression signiﬁcantly enhanced, whereas anti-miR-151a
signiﬁcantly reduced A549 cell growth, as compared to control
A549 cells (Figure 2a, P= 0.005, P= 0.0045 and Supplementary
Figure S4A). We veriﬁed that this was not an A549 cell line speciﬁc
phenomena, as miR-151a also signiﬁcantly enhanced H23 and
H1299 tumor cell proliferation, and anti-miR-151a signiﬁcantly
decreased tumor cell proliferation, relative to miR control H23 and
H1299 cells (Figures 2b and c). These results suggest that NSCLC
cells with different genetic aberrations (A549: p14ARF and KRAS
mutations), (H23: KRAS and PTEN mutations) and (H1299: NRAS
mutations and p53-null) are sensitive to changes in miR-151a
expression levels. Next we performed colony-formation assays and
obtained comparable results for miR modulated A549 cells
(Figure 2d, P= 0.0003 and Po0.0001). In addition, A549 cells
were transiently transfected with miR mimic oligonucleotides
(miR-151a, anti-miR-151a or miR control mimics). These
experiments showed a similar effect on tumor cells growth
(Figure 2e, P= 0.0472 and P= 0.0366, and Supplementary
Figure S4B), demonstrating that the observed effect of
stably induced miRs, are not likely to be an artifact of
lentiviral genomic integration. Furthermore, we generated an
anti-miR-151a/miR-151a double expressing A549 cell line. Adding
Figure 1. miR-151a expression is induced in NSCLC. (a) miR-151a expression levels were characterized by miR-speciﬁc RT-qPCR analysis in a
NSCLC (LAC) cohort comprising 52 primary LACs and 26 paired distant metastases (22 brain and 4 adrenal gland), as well as 10 tumor-adjacent
normal lung samples. Relative expression is shown as a dot plot with mean± s.e.m. in each group indicated. (b) In situ hybridization using
scrambled miR-control and miR-151a probes of normal, primary lung tumor (‘T’) and metastatic (‘M’) tissue. Areas with normal lung and brain
cells are indicated with triangles and circles, respectively. High miR expression is shown as blue/purple, low expression is shown as light pink.
One representative example shown of 3. (c) miR-151a expression in paired tumor and tumor-adjacent normal lung samples from 45 LAC
patients. Expression data from all LAC patients with paired specimens available were downloaded from The Cancer Genome Atlas webpage
(https://cancergenome.nih.gov/) and log2 transformed. Red or blue lines indicate paired samples with increased or decreased miR-151a
expression in the tumor tissue, respectively. **Po0.01, ****Po0.0001; by two-tailed unpaired (a) or paired (c) Student’s t-test.
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miR-151a back into anti-miR-151a A549 cells rescued the
anti-growth effect, indicating that overexpressed miR-151a is
indeed required for anti-miR-151a reduced A549 tumor cell
growth (Figure 3e, anti-miR-151a: Po0.0001 and Supplementary
Figure S4C). Finally, miR-modulated primary human lung
endothelial cells, (hLECs) were analyzed, suggesting that the
proliferative advantage of miR-151a, and that anti-miR-151a’s
cytostatic effects are selective to NSCLCs, relative to the analyzed
hLECs (Figure 3g and Supplementary Figure S4D).
miR-151a increases NSCLC cell motility
Successful tumor cells acquire enhanced migratory and invasive
properties. We next tested if miR-151a plays a role in NSCLC cell
motility. miR modulated (miR-151a, anti-miR-151a and control
miR) cell lines were pre-treated with mitomycin c, a cell cycle
inhibitor (Supplementary Figure S5A), allowing us to study effects
on migration, separate from proliferation. First the classical wound
healing assays was performed. miR-151a A549 cells were capable
of healing the induced wound at a signiﬁcantly increased rate, as
opposed to anti-miR-151a A549 cells, which showed signiﬁcantly
reduced wound healing, relative to control miR A549 cells
(Figure 3a, **P= 0.0059, *P= 0.0196 (transduced cells).
Similar results were obtained using transfection of miR mimics
(Figure 3a, miR-151a: P= 0.0005 and Supplementary Figure S5B).
We tested and veriﬁed that miR-151a regulation (miR-151a versus
anti-miR-151a) substantially increased versus reduced wound
healing, relative to miR control in both H23 cells and H1299 cells
(Figures 3b and c, H23: *P= 0.0304, H1299: *P= 0.0499 and
Supplementary Figures S5C and D). In addition, we performed
transwell migration assays and in vitro invasion assays, to further
evaluate miR-151a’s regulatory role in NSCLC cell motility.
As expected miR-151a A549 cells migrated through the transwells
Figure 2. miR-151a enhances NSCLC cell growth. Cell proliferation of miR-modulated (miR-CTL, miR-151a and anti-miR-151a) (a) A549 cells,
(b) H1299 cells and (c) H23 cells were analyzed by culturing cells at low density and counted for 4 days. (d) Colony Formation Assays of
miR-modulated A549 cells. Representative images for each treatment are shown. Scale bar= 1000 μm. (n= 3, independent biological
experiments, 3 technical replicates of each). (e) Growth analysis counting A549s transfected with miR-CTL, miR-151a or anti-miR-151a
oligonucleotides (miR-mimics). (n= 3 independent cell cultures and experiments, 3 technical replicates for each). (f) Growth analysis counting
A549s stably expressing miR-CTL, anti-miR-151a or both miR-151a and anti-miR-151a (n= 3 independent cell cultures and experiments, 3
technical replicates for each). (g) Growth analysis counting human lung endothelial cells (hLECs) stably expressing miR-CTL, miR-151a and
anti-miR-151a. (n= 1 biological replicate, 3 technical replicates of each). Throughout ﬁgure, all graphs are shown as mean± s.e.m. *Po0.05;
**Po0.01; ***Po0.001; ****Po0.0001 by two-tailed Student’s t-test.
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at a signiﬁcantly increased rate, and anti-miR-151a A549 cells
migrated less efﬁciently, as compared to control miR A549 cells
(Figure 3e, ***P= 0.001 and **P= 0.0053 and Figure 3f, miR-151a:
****Po0.0001, anti-miR-151a: ***Po0.0007). In summary, these
results support the idea that miR-151a signiﬁcantly enhances the
potential for NSCLC tumor cell migration and invasion and that
neutralization of miR-151a results in a substantial reduction in
NSCLC cell motility.
miR-151a induces a mesenchymal-like morphology of NSCLCs
Based on an observed change in tumor cell morphology we next
initiated quantitative analysis comparing the morphology of
Figure 3. miR-151a enhances NSCLC cell migration and invasion and anti-miR-151a reduces cell motility. (a) Stably (Images and left graph) or
transiently (right graph) miR-modulated A549 cells (miR-CTL, miR-151a or anti-miR-151a) were pre-treated with mitomycin c for 2 h and then
migration was analyzed by scratch assay. Representative images are shown, scale bar=500 μm. (n=3 independent cell cultures and experiments).
Scratch assays were also performed for stably miR-modulated (b) H23 cells and (c) H1299 cells. (d) Migration of mitomycin c pretreated
miR-modulated A549 cells was analyzed by performing transwell migration assays for 6 h, at which point migrated cells were stained with DAPI
and counted. Representative images are shown, scale bar=200 μm (n=3 independent cell cultures and experiments, 3 technical replicates of
each). (e) Invasion assay were performed using stable miR-expressing A549s pre-treated with mitomycin c and allowed to migrate for 12 h.
Representative images are shown, scale bar=200 μm (n=2 independent cell cultures and experiments, 3 technical replicates of each). Throughout
ﬁgure, all graphs are shown as mean± s.e.m. *Po0.05; **Po0.01; ***Po0.001; ****Po0.0001 by two-tailed Student’s t-test.
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untreated, miR modulated and NSCLC cells stimulated with TGF-β,
which is a strong inducer of EMT.7 We determined that miR-151a is
an inducer of a mesenchymal-like morphology of A549 cells
(spindle-formed, far separated cells), relative to untreated and
miR control A549 cells, though not to the extent of TGF-β
(Figure 4a, miR-151a: mesenchymal = 77.7%, epithelial = 17.7%,
undeﬁned= 4.6% and Supplementary Figure S2). Anti-miR-151a
cells showed an epithelial-like cell phenotype (cobblestone
shaped, cluster formation), similar to that of parental A549 cells
(Figure 4a, anti-miR-151a: mesenchymal = 6.4%, epithelial = 91.6%,
undeﬁned= 2.0% and Supplementary Figures S6 and S7).
Similar results were obtained using miR modulated H1299 cells.
Interestingly, in addition to the effect of miR-151a, anti-miR-151a
consistently showed an effect on H1299 cells by decreasing
the percentage of mesenchymal-like cells, relative to miR
control H1299 cells (Figure 4b). These results suggest that
miR-151a overexpression induces a conversion of the character-
istic epithelial cell phenotype of NSCLC cells (A549 and H1299
cells) to a partial mesenchymal-like phenotype, and suggests that
anti-miR-151a can reduce these cellular traits characteristic of
tumor cell progression in NSCLC cells (H1299 cells).
miR-151a reduces E-cadherin in NSCLC cells
Our ﬁnding that miR-151a induces a mesenchymal-like
morphological phenotype and enhances NSCLC cell migratory
Figure 4. miR-151a induces a mesenchymal-like phenotype and anti-miR-151a enhances an epithelial cell-like phenotype of NSCLC cells. Images
(top panels) of (a) A549 cells and (b) H1299 cells untreated, treated with TGF-β, or stably transduced with miR-CTL, miR-151a or anti-miR-151a.
Column 1: Bright ﬁeld (Scale bar=400 μm), Column 2: Bright ﬁeld (scale bar=100 μm). The relative proportion of mesenchymal, epithelial, or
undeﬁned cells were quantiﬁed and shown as stacked bar percentage plots (lower panels). The relative proportion of mesenchymal cells was
compared between treatments using two-tailed Student’s t-test. One representative image shown of three independent cell cultures and
experiments. Throughout ﬁgure, all graphs are shown as mean± s.e.m. **Po0.01; ***Po0.001; ****Po0.0001 by two-tailed Student’s t-test.
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potential (Figures 3a and 4), suggests that miR-151a induces
partial EMT of lung cancer cells. Following up on these ﬁndings we
next performed RT-qPCR analysis of miR-modulated A549 cells
and found that miR-151a overexpression resulted in signiﬁcantly
induced expression levels of Fibronectin and Slug mRNA
(Figure 5a, P= 0.008 (ﬁbronectin) and P= 0.0001 (Slug)), and
anti-miR-151a resulted in reduced expression levels of Fibronectin
and Slug mRNA, relative to controls (Figure 5a, Po0.0001 (Slug)).
It has previously been determined that Slug represents one of the
major master regulators of EMT in lung cancer.20 In addition,
miR-151a signiﬁcantly reduced the expression levels of E-cadherin
and anti-miR-151a enhanced E-cadherin mRNA expression levels,
relative to controls (Figure 5a, Po0.0001). Expression levels of
Snail, Twist and ZEB1 mRNA were not signiﬁcantly increased (data
not shown). Loss of E-cadherin is considered to be a fundamental
event in EMT and many transcription factors are known to repress
E-cadherin during EMT, including Slug.6–9 We next wished
to determine whether miR-151a reduces E-cadherin protein
expression levels. Confocal analysis of E-cadherin expression of
miR modulated A549 cells showed that overexpression of
miR-151a signiﬁcantly reduced the expression levels of E-cadherin,
and anti-miR-151a enhanced E-cadherin protein expression, as
compared to control cells (Figure 5b, Po0.0001 and P= 0.0026).
Western blot analysis also conﬁrmed a signiﬁcant effect of
miR-151a on E-cadherin protein levels and a similar trend
was seen for anti-miR-151a (Figure 5c, miR-151a: Po0.0001,
anti-miR-151a: P= 0.1017). Next, we wished to study E-cadherin
expression in NSCLC patient specimens. First we determined
Figure 5. miR-151a reduces E-cadherin expression in NSCLC cells. (a) The relative expression levels of E-cadherin (left), ﬁbronectin (middle) and
Slug (right) were determined in stably miR-transduced A549 cells by RT-qPCR. (n= 3 independent cell cultures and experiments, 3 technical
replicates of each). (b) Representative confocal images of stably transduced A549s immunoﬂuorescently stained with E-cadherin.
Scale bar= 10 μm. Relative ﬂuorescence levels are quantiﬁed of the shown biological replicate (n= 3 independent cell cultures and
experiments, 12 technical replicates of each). (c) Immunoblot analysis of E-cadherin and tubulin protein levels in A549s transduced with miR
constructs. Relative levels are quantiﬁed. One representative example of three is shown. (d) The expression levels of miR-151a was analyzed by
in situ hybridization and compared with the expression of E-cadherin determined by immunohistochemical staining in three normal lung
samples and 3 primary LACs (miR-151a expression: high=purple, low= light pink, E-cadherin expression: high=pink, low=blue). Cytokeratin
7 was included to identify cells of epithelial origin, for example, adenocarcinoma cells. Scale bar= 50 μm. Throughout ﬁgure, all graphs are
shown as mean± s.e.m. *Po0.05; **Po0.01; ***Po0.001; ****Po0.0001 by two-tailed Student’s t-test. Uncropped version of blot is shown in
Supplementary Figure S8.
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E-cadherin expression levels in the 52 primary NSCLC samples by
RT-qPCR using RNA extracted from whole tissue sections, and
compared the levels to those determined for miR-151a in each
sample (Figure 1a). No inverse correlation between miR-151a and
E-cadherin expression was detected (Supplementary Figure S9A),
possibly because of the low and varying percentages of
tumor tissue in the samples (mean= 33.2%, range= 5–80%,
Supplementary Table S1). Next we performed immunohistochem-
ical analysis of E-cadherin expression in normal lung and primary
NSCLC tumor (Figure 5d). We were surprised to ﬁnd that both
miR-151a and E-cadherin showed strong positive staining in
NSCLC (Area without EMT), as compared to normal lung
(Figure 5d). When comparing E-cadherin and miR-151a expression
between areas within the same slide where EMT was absent
versus had occurred, we were able to identify areas which
showed the expected inverse correlated between miR-151a and
E-Cadherin (high versus low). However, the variation in both
miR-151a and E-cadherin staining intensity across and between
slides rendered direct comparison inappropriate. We also
evaluated the expression of E-cadherin and miR-151a in the
NSCLC area without EMT (Figure 5d), and interestingly we
observed that miR-151a expression was higher in the tumor
tissue (‘T’) as compared to the epithelial cells in the adjacent
bronchiole (‘Br’), which represents normal lung tissue. The inverse
relationship was seen for E-cadherin, which was expressed at
higher levels in the bronchiole (‘Br’) as compared to the tumor
cells (‘T’). This is an important observation for two reasons, (1) the
bronchiole and tumor tissue were immediately adjacent to each
other and the differences in miR-151a and E-cadherin expression
between the bronchiole and tumor tissue was therefore not a
result of variation in staining intensity across the slide and (2)
both epithelial cells from the bronchiole as well as the NSCLCs
are believed to derive from the same stem cells within the
lung epithelial cell tissue.21 However, further analysis is needed
to demonstrate whether miR-151a is regulating E-cadherin
expression in vivo.
miR-151a interacts with the coding sequence of E-cadherin mRNA
We next wished to determine if E-cadherin mRNA is a direct target
of miR-151a. When performing bioinformatics analyses of
potential miR-151a binding sites in E-cadherin mRNA, we
identiﬁed the same identical (6-mer) seed match at three different
locations in the coding sequence (CDS) of E-cadherin mRNA,
named site #1, site #2 and site #3 (Figure 6a). In order to
determine whether the predicted 6-mer seed sequence, was
required for miR-151a binding we performed a series of
E-cadherin luciferase reporter assays, in which fragments of the
E-cadherin CDS including either site #1, site #2 or site #3 were
cloned into a luciferase reporter construct. HeLa cells were
transfected with one of the three E-cadherin CDS-luciferase-
encoding plasmids in the presence of either mature miR-151a or
miR control mimics. HeLa cells transfected with miR-151a and
encoding binding site #1, #2 and #3 all showed modest but
Figure 6. miR-151a interacts with E-cadherin mRNA. (a) Schematic representation of three potential 6-mer miR-151a-binding sites in the
coding DNA sequence (CDS) of E-cadherin mRNA. (b) Relative luciferase levels in A549 cells transfected with constructs expressing the wild
type (WT) binding sequences at site #1, #2 or #3, along with miR-CTL or miR-151a mimics, were determined 48 hr after transfection. (n= 3
independent cell cultures and experiments, 3 technical replicates of each). (c) Schematic of miR-151a binding to WT or mutant E-cadherin
mRNA. Relative luciferase levels of A549 cells transfected with constructs expressing WT or mutated (site #2) binding sequences and miR-CTL
or miR-151a mimics were determined 48 hr after transfection. (n= 3 independent cell cultures and experiments, 3 technical replicates of each).
(d) Schematic of Argonaute immunopuriﬁcation strategy for miR-RNA complexes (Ago-RIP). (e) A549 cells stably expressing either miR-151a or
anti-miR-151a were generated. Relative levels of E-cadherin, RhoGDIA and GAPDH mRNA in input and Ago-RIP (IP) fractions were determined.
‘Corrected’ indicates mRNA levels in IP fractions when normalized to the mRNA level in corresponding input fractions. (n= 3 independent cell
cultures and experiments, 3 technical replicates of each). Throughout ﬁgure, all graphs are shown as mean± s.e.m. *Po0.05; **Po0.01;
***Po0.001; ****Po0.0001 by two-tailed Student’s t-test.
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signiﬁcantly reduced luciferase activity (Figures 6a and b, #1
P= 0.0005, #2 P= 0.0002, #3 P= 0.0255). Next, mutations were
introduced into the 6-mer seed site of E-cadherin CDS (site #2) to
determine if this speciﬁc nucleotide sequence is required for the
interaction with miR-151a (Figure 6c). Luciferase activity was again
signiﬁcantly lower in HeLa cells transfected with miR-151a mimic
and WT E-cadherin, relative to miR control mimic suggesting that
miR-151a can bind to the WT E-cadherin mRNA sequence and
prevent the translation of luciferase (Figure 6c, P= 0.0021). In
contrast, HeLa cells transfected with miR-151a mimic and the
mutant 6-mer E-cadherin CDS site, exhibited de-repressed
luciferase activity to the same levels as the WT E-cadherin and
miR-control cells; consistent with the idea that miR-151a no longer
binds and represses reporter gene expression (Figure 6c).
Next we performed Argonaute (Ago)-miR immunopuriﬁcation
analysis. In brief, Ago complexes containing miRs and target
mRNAs were isolated by immunopuriﬁcation and assessed for
relative complex occupancy by the E-cadherin mRNA by qRT-PCR
to determine if miR-151a directly targets E-cadherin mRNA in
A549 cells (Figure 6d), as previously described.22 The relative level
of E-cadherin mRNA was signiﬁcantly lower in cells stably
overexpressing miR-151a when compared to those expressing
anti-miR-151a constructs, as expected (Figure 6e, P= 0.0010).
Despite the increased levels of E-cadherin mRNA (because of
lower miR-151a expression levels), which may underestimate the
scale of the effect, the relative fraction of Ago-bound E-cadherin
mRNA signiﬁcantly increased when miR-151a was overexpressed
(Figure 6e, IP, P= 0.0018). When correcting for the lower
expression level of E-cadherin mRNA, the increase in miR-151a
bound E-cadherin mRNA was even more signiﬁcant (Figure 6e, IP,
P= 0.0002). In contrast, miR-151a did not repress GAPDH mRNA
expression levels or immunepurify GAPDH mRNA, as expected
(Figure 6f). As a positive control we immune puriﬁed a different
miR-151a target mRNA, RhoGDIA.24 As expected miR-151a
signiﬁcantly reduced the expression levels of RhoGDIA mRNA,
and miR-151a immunepuriﬁed signiﬁcantly more RhoGDIA mRNA
as compared to anti-miR-151a A549 samples (Figure 6g Input,
P= 0.0116, IP, Po0.0001). These data combined, support the idea
that miR-151a represses E-cadherin expression via a direct
interaction with the target site on the E-cadherin CDS mRNA.
Figure 7. E-Cadherin is a functional target of miR-151a-induced partial EMT. (a) Schematic representation showing miR-151a binding to WT or
mutant (silent mutant) E-cadherin mRNA (miR-151a resistant E-cadherin, left panel). Immunoblot analysis of E-cadherin and GAPDH protein
levels in A549 cells transduced with miR-151a resistant E-cadherin or control constructs (middle panel). Relative levels are quantiﬁed (right
panel). (b) Migration of mitomycin c pre-treated A549 cells (images and left graph), H23 cells (middle graph) and H1299 cells (right graph)
transduced with miR-CTL or miR-151a and miR-151a resistant E-cadherin or control constructs were assessed by wound healing assay at time
0 and 6 h. Representative images (left panels), scale bar= 500 μm. (n= 3 independent cell cultures and experiments, 3 technical replicates of
each). (c) Transwell migration assay using A549s transduced with miR-CTL or miR-151a and miR-151a resistant E-cadherin or control
constructs. Cells were pre-treated with mitomycin c, plated at the top of a transwell and allowed to migrate for 6 h. Representative images are
shown (left panels, scale bar= 400 μm. (n= 3 independent cell cultures and experiments, 3 technical replicates of each). (d) Images of A549
cells transduced with miR-CTL or miR-151a and miR-151a resistant E-cadherin or control constructs. Representative images are shown (left
panel), scale bar= 400 μm. The relative proportion of mesenchymal, epithelial, or undeﬁned cells were quantiﬁed and shown as a stacked bar
percentage plot (right panel). The relative proportion of mesenchymal cells was compared between treatments using two-tailed Student’s t-
test. (n= 3 independent cell cultures and experiments, three technical replicates of each). Throughout ﬁgure, all graphs are shown as
mean± s.e.m. *Po0.05; **Po0.01; ***Po0.001; ****Po0.0001 by two-tailed Student’s t-test.
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However, further characterization demonstrating whether the
proposed sites are functional in the context of the full length
coding region, is warranted.
Importantly genomic alignment analysis of human, gorilla, giant
panda, leopard, mouse and cat sequences showed that the
miR-151a-binding sites in E-cadherin coding region sequence are
100% conserved for site#3 between all 6 species, and that binding
site#1 and site#2 are 100% conserved between human and mouse
versus human and Gorilla, and partly conserved (one–three
mismatches) in the remaining alignment analysis (Supplementary
Figure S9B).
E-cadherin is a functional target important for miR-151a-induced
partial EMT
As miRs are known to target multiple, even hundreds of mRNAs,
we wished to evaluate the signiﬁcance of E-cadherin as a direct
functional mediator of the miR-151a-induced proliferation and
partial EMT, including migration. We generated an E-cadherin
over-expressing plasmid in which the miR-151a binding site was
mutated by creating silent mutations in the 6-mer-binding site
(called miR-151a resistant E-cadherin) (Figure 7a, left panel). We
veriﬁed that E-cadherin was induced in E-Cadherin induced A549
cells relative to A549 control cells (Figure A, middle and right
panel). First, we determined that ectopic E-cadherin expression
did not speciﬁcally rescue miR-151a-induced proliferation (data
not shown). Next, we examined the effect of miR-151a resistant
E-cadherin, on NSCLC cell migration by performing scratch assay
rescue experiments. Ectopic E-cadherin expression reduced
miR-151a-induced migration, as determined by wound healing
assays of A549, H23 and H1299 miR-modulated cells (Figure 7b,
A549: **** Po0.0001, H23: * P= 0.0237). In addition, E-cadherin
over-expression in miR-151a A549 cells reduced A549 cell
migration as determined by transwell migration assays
(Figure 7c, P= 0.0014). Finally, we analyzed the effect on NSCLC
cell morphology and determined that introduction of miR-151a
resistant E-cadherin into miR-151a over-expressing cells, partially
rescued the effect of miR-151a, as the transition into a
mesenchymal-like phenotype was greatly reduced (Figure 7d,
** P= 0.0094). In summary, we propose a model for
oncomiR-151a-induced partial EMT in NSCLC cells, in which
miR-151a directly targets the CDS of E-cadherin and represses
the expression of E-cadherin protein, resulting in a signiﬁcant
growth advantage and the induction of a mesenchymal-like
transition including enhanced motility.
DISCUSSION
In the present study we demonstrate for the ﬁrst time that
miR-151a functions as an oncomiR in NSCLC. We ﬁnd that
miR-151a is signiﬁcantly increased in NSCLC tumor specimens as
compared to normal lung tissue and that ectopic miR-151a
expression signiﬁcantly enhances NSCLC cell proliferation, but
does not signiﬁcantly affect normal lung endothelial cell growth.
In addition, overexpression of miR-151a induces a partial EMT
phenotype of NSCLCs cells as determined by a change in cell
morphology and signiﬁcantly enhanced cell motility and invasive
properties. The functional characteristics of miR-151a NSCLC cells,
correlates with a signiﬁcant decrease of E-cadherin expression and
increases of Fibronectin and Slug expression levels, which are
considered fundamental events in EMT. Direct interaction analyses
by luciferase reporter assays and miR-Ago immunopuriﬁcation
methods support the idea that miR-151a regulates E-cadherin
expression and that miR-151a directly binds to seed sequence
matches in the coding region sequence. Importantly, genomic
alignment analysis demonstrated sequence conservation of the
miR-151a binding sites in the E-cadherin coding region sequence
(in particular of site#3) between species.
However, an alternative explanation for the effect of miR-151a
on E-cadherin is that the remarkable upregulation of Slug by
miR-151a leads to the repression of E-Cadherin transcription.
At this point the mechanism by which overexpression of
miR-151a results in signiﬁcant induction of Slug (and ﬁbronectin)
mRNA expression levels is unknown. We are in the process of
investigating possible different scenarios, namely whether
miR-151a targets a negative regulator of Slug, resulting in the
increase in Slug expression. An alternative explanation could be
aligned with a previously reported ﬁnding by Onder et al.,23
demonstrating that E-cadherin loss can results in the induction of
multiple transcription factors including Twist and Zeb-1 in breast
cancer cells (Onder et al.23). However, the argument that the
upregulation of Slug is a consequence, rather than a cause, of
E-Cadherin repression is weakened by the fact that neither Zeb1
nor Twist were induced in the NSCLC cell lines studied. As such,
the upregulation of Slug merits further investigation. Additional
work is also required to address the question as to how miR-151a
is regulated and induced. Pilot experiments suggest that TGF-beta
does not induce miR-151a expression levels in NSCLC cells.
Furthermore, induced miR-151a resistant E-cadherin
overexpression in miR-151a NSCLC cells abrogated the induced
partial EMT transition and migration advantage of miR-151a
NSCLC cells, indicating that E-cadherin is an important functional
target of miR-151a-induced migration. Additional work is needed
to determine which miR-151a targets are responsible for the
observed NSCLC cell growth advantage. The ﬁnding that miR-151a
overexpression also signiﬁcantly induces the expression levels of
ﬁbronectin and Slug in A549 cells, suggests that miR-151a may be
involved in the regulation of a complex network of proteins
involved in EMT. The importance of a role for miR-151a’s in NSCLC
EMT is emphasized by the recent ﬁnding that NSCLC cells
featuring partial EMT (hybrid epithelial/mesenchymal phenotype)
are endowed with higher cancer-initiating stem cell (CIC) plasticity
and a signiﬁcant shorter overall survival.20
Based on the signiﬁcant decrease/loss of E-cadherin protein
expression in our A549 cell studies, we were surprised to ﬁnd that
NSCLC patient specimens showed E-cadherin staining at varying
degrees, even in the presence of signiﬁcant miR-151a expression,
as determined by in situ hybridization. This is likely a result of
heterogeneity of the tumor. However, comparison of normal
epithelial cell tissue (bronchiole) to tumor epithelial cells (NSCLC)
within the same slide, indicates that NSCLC cells are characterized
by high miR-151a expression and lower E-cadherin expression as
compared to bronchiole tissue, which would be in agreement with
our in vitro results.
In conclusion, our results strongly suggest that miR-151a
functions as an oncomiR in NSCLC pathogenesis, by promoting
tumor cell growth and inducing partial EMT, through the
regulation of key gene products including E-cadherin, Fibronectin
and Slug. Furthermore, we have determined that E-cadherin, a
direct and functional target of miR-151a, can potently inhibit
NSCLC cell migration and the transition to a mesenchymal-like
cell phenotype, indicating that miR-151a-induced E-cadherin
repression is a primary mechanism by which miR-151a enhances
partial EMT of NSCLC. The identiﬁcation of E-cadherin as a
primary target of oncomiR-151a provides new insights into
the understanding of the complex processes of partial NSCLC
EMT, and may facilitate the development of potential therapeutics
against NSCLC.
MATERIAL AND METHODS
Patient samples
Formalin-ﬁxed, parafﬁn embedded surgical specimens from 52 LAC
(NSCLC) patients, for more details.25 The study was approved by the
Regional Ethical Committee (Permission No.: 1-10-72-20-14) and all
experiments were conducted in accordance with this approval.
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Cell culture, plasmids and treatments
Cells were incubated at 37 °C and 5% CO2 and routinely checked
for mycoplasma contamination. Mouse lung endothelial cells (mLEC;
C57-6011, Cell Biologics) were maintained in complete mEC media (M1168,
Cell Biologics, Chicago, IL, USA) and 10% FBS (FB-02, Omega Scientiﬁc,
Tarzana, CA, USA). Human lung EC (hLEC; #3000, ScienCell, Carlsbad, CA,
USA) were maintained on plates coated with 10 μg/ml ﬁbronectin (F2006,
Sigma-Aldrich, St. Louis, MO, USA) in EC media (1001, ScienCell). Human
NSCLC cell lines A549 (CCL-185), HEK293T (CRL-3216), H23 (CRL-5800) and
NCI-H1299 (CRL5803) from American Tissue Cell Culture (ATCC)
were cultured in DMEM (25-501N, Genesee, San Diego, CA, USA) and
RPMI (SH30027FS, ThermoFisher, Hamton, NH, USA) medium, HeLa cells
(CCL-2, ATCC) in EMEM (SH3024401, Hyclone, Anaheim, CA, USA)
respectively, with 10% FBS. Five ng/ml TGF-β was added to some cultures
(Peprotech, Rocky Hill, NJ, USA, Cat 100-21). All cell lines were tested for
mycoplasma contamination routinely.
Plasmids used: mutations were introduced into an E-cadherin pcDNA
overexpression plasmid (45769, Addgene, Cambridge, MA, USA) using the
GeneArt Site-directed Mutagenesis System (A13282, Life Technologies,
Carlsbad, CA, USA).
RNA extraction and RT-qPCR
For all cell lines, RNA extraction and RT-qPCR experiments were conducted as
previously described.22 From each formalin-ﬁxed, parafﬁn embedded patient
sample, RNA was extracted from a 1×7 μm section using the miRNeasy FFPE
kit (217504, Qiagen, Germantown, MD, USA). miR expression analysis was
performed using the miRCURY LNA Universal RT microRNA PCR system
(203301, Exiqon, Woburn, MA, USA), whereas mRNA expression analysis was
performed using the High Capacity Reverse Transcriptase Kit (4368813, Life
Technologies) and TaqMan PreAmp Master Mix kit (4384267, ThermoFisher)
according to manufacturer’s protocol. All RT-qPCR was performed in
technical cDNA and qPCR duplicates using either hsa-miR-103a-3p and
hsa-miR-423-5p or IPO8 and PUM1 as reference genes, as they have
previously been reported stably expressed in NSCLC.25,26 All data was
analyzed using NormFinder to ensure stability of the reference genes.27 For
each sample, relative quantities were calculated as 2−ΔCt and determined as
the average relative quantities in the cDNA synthesis duplicates.
In situ hybridization and immunohistochemistry
For in situ hybridization analysis of miR-151a expression, a 5′- and
3′-double digoxigenin-labeled miRCURY LNA microRNA Detection Probe
(612499-360, Exiqon) was used following manufacturer’s protocol.
Scrambled probe and U6 were included as controls. Brieﬂy, the
deparafﬁnized, proteinase K-digested and dehydrated sections were
hybridized with 40 nM double-DIG LNA hsa-miR-151a-5p probe for
60 min at 50 °C. After a series of stringent washes with saline-sodium
citrate buffer, sections were blocked then incubated with 1:125 dilution of
anti-DIG Fab fragments conjugated to alkaline phosphatase (11093274910,
Roche Diagnostics, Indianapolis, IN, USA). After 30 min, the anti-DIG/AP was
repNSCLCed with fresh reagent and incubated for an additional 30 min.
The signal was detected using freshly prepared NBT/BCIP AP substrate (11-
681-451-001, Roche Diagnostics). After 60 min at 30 °C, fresh AP substrate
was added and incubated for 60 min. Finally, slides were counterstained
with Nuclear Fast Red (H-3403, Vector laboratories, Burlingame, CA, USA).
Immuhistochemical staining was performed routinely using the VENTANA
BenchMark XT staining system (Roche Diagnostics) with antibodies against
E-cadherin (790-4497, Ventana, Roche Diagnostics) and cytokeratin 7 (790-
4462, Ventana, Roche Diagnostics) according to manufacturer’s protocol.
Transfection and transduction of miRs
Transient transfection: 20 nM miRIDIAN microRNA mimics or inhibitors
from GE Dharmacon, Lafayette, CO, USA (Control #2 (CN-002000-01-05),
hsa-miR-151a-5p mimic (C-301086-01-0005), and hsa-miR-151a-5p Hairpin
Inhibitor (IH-301086-02-0005)) using OptiMEM (31985070, ThermoFisher)
and Lipofectamine RNAiMAX (13778150, ThermoFisher).
Stable transduction: VSV-G-pseudotyped lentiviral particles were
made by transfecting 5.3 μg of pMD2-G (12259, Addgene), 9.7 μg of
pCMV-DR8.74 (8455, Addgene) and 15 μg pCD510B-1 (miR Control), mZIP,
pCD510B-1-miR-151a or mZIP-anti-miR-151a into 293T cells using
Lipofectamine LTX (15338030, ThermoFisher).22 Transduced cells were
selected and maintained using 10 μg/ml puromycin or 10 μg/ml
blasticidin.
Cell proliferation and colony formation assays
Cells were plated at low density (6 well plates at 2 × 104 cells/well) in
triplicate and counted or plated in 6 well plates at 200 cell/well in triplicate,
cultured for 2 weeks, stained (0.1% crystal violet solution (C0775, Sigma),
0.3% acetic acid, 99.6% ethanol) and the area of colonies were determined.
In vitro migration and invasion assays
Cells were pre-treated with 10 μg/ml mitomycin c (BP25312, Fisher
Scientiﬁc, Hampton, NH, USA) for 2 h. Conﬂuent cells were scratched and
imaged after 6 or 14 h and the percent healed was calculated.
Transwell migration assay: 6.5 mm transwells with (8 μm) inserts (3464, Corn-
ing, Corning, NY, USA) were coated for 2 h with 10 μg/ml ﬁbronectin (F2006,
ThermoFisher). Migrated cells were ﬁxed, stained with DAPI and counted.
Invasion assay: 8 μm PET inserts coated with Matrigel (354480, Corning)
were used. After 12 h invasion was determined as in transwell experiments.
Immunoﬂuorescent staining
Cells were plated on gelatin-coated coverslips, ﬁxed in 4% paraformalde-
hyde (Sigma-Aldrich), incubated in blocking buffer (1% bovine serum
albumin, 0.3% Triton X-100 (ThermoFisher) in PBS), stained with 10 μg/ml
goat anti-human E-cadherin antibody (AF648, R&D Systems, Minneapolis,
MN, USA) followed by Donkey anti-Goat IgG secondary antibody conjugated
to Alexa Flour 488 (A11055, ThermoFisher). Coverslips were mounted on
slides with VectaSheild with DAPI (H-1200, Vector Laboratories) and cells
imaged at 63x on a Zeiss spinning disk confocal microscope.
Western blot
Cells were lysed in RIPA buffer (89901, ThermoFisher) with inhibitor
cocktail (PI78410, ThermoFisher). 4x LDS sample buffer (NP0008,
ThermoFisher) was used, samples boiled at 95 °C for 10 min. NuPAGE
Novex 4-12% Bis–Tris Protein Gels (NP0335, ThermoFisher Scientiﬁc),
PVDF membranes, Blocking (PBST 5% nonfat milk), primary antibodies
E-cadherin (3195S, Cell Signaling, Danvers, MA, USA) or tubulin (ab4074,
abcam, Cambridge, MA, USA), secondary antibody (HRP-linked anti-rabbit
IgG antibody, 7074S, Cell Signaling) and Pierce ECL Western Blotting
Substrate (32106, ThermoFisher) and Bio-Rad, Hercules, CA, USA ChemiDoc
XRS+ System were used for protein expression development.
Luciferase assay
Wildtype or mutated E-cadherin sequences from the coding region sequence
(CRS) were cloned into a dual luciferase reporter plasmid (pEZX-
MT05, Genecopoeia, Rockville, MD, USA). 3×105 HeLa cells were forward-
transfected with 0.8 μg reporter plasmid and 20 nM control mimic or miR-151a
mimic with Attractene transfection reagent (301005, Qiagen) according to the
manufacturer’s instructions. Relative Gaussia luciferase and secreted alkaline
phosphatase were determined with the Secrete-Pair Dual Luminescence Assay
Kit (SPDA-D010, Genecopoeia) on a Tecan Inﬁnite F200 microplate reader.
Argonaute RNA immunopuriﬁcations
Immunopuriﬁcation of Argonaute from A549 cell extracts was performed
using the 4F9 antibody (4F9, Santa Cruz Biotechnology, Dallas, TX, USA) as
described previously.22 Results were normalized to their inputs and shown
as ‘corrected’ values as a proxy for Ago immunopuriﬁcation efﬁciency.
Analysis of published data using The Cancer Genome Atlas
database
The data was retrieved from https://gdc-portal.nci.nih.gov/. All hsa-mir151a
expression values from the 45 patients with paired samples, normal lung
tissue (sample type 11A) and tumor tissue (sample type 01A) were collected.
Statistical analysis
Student’s t-tests were used to calculate two-tailed P-values and data are
displayed as mean± s.e.m. of technical or independent biological
replicates, (n) as indicated.
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